---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000028"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:17:34.887841+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Zentalis appoints Iris Roth as COO, effective Feb 13, 2023

## Summary
- Iris Roth, Ph.D. appointed Chief Operating Officer effective February 13, 2023.
- Dr. Roth previously led CD226 Axis immune checkpoint inhibitor development at GSK as VP Medicine Development Leader.
- Initial base salary $434,476; target bonus 40% of base; severance for involuntary termination.
- Granted stock options for 297,500 shares and RSUs for 52,500 shares, vesting four years.
- Severance includes 9 months salary (12 months after change in control) and COBRA coverage.

## SEC filing metadata
- accession: 0001725160-23-000028
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/0001725160-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/zntl-20230213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000028
- JSON: https://secwatch.observer/filing/0001725160-23-000028.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000028.txt

## Key facts
- Executive change
  Iris Roth was appointed as Chief Operating Officer at Zentalis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/0001725160-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.